Carboplatin + Pembrolizumab
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Fallopian Tube Carcinoma
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Trial Timeline
Mar 14, 2017 → Dec 31, 2021
NCT ID
NCT03029598About Carboplatin + Pembrolizumab
Carboplatin + Pembrolizumab is a phase 1/2 stage product being developed by Merck for Recurrent Fallopian Tube Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03029598. Target conditions include Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Fallopian Tube Carcinoma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03213041 | Phase 2 | Recruiting |
| NCT03029598 | Phase 1/2 | Completed |
Competing Products
20 competing products in Recurrent Fallopian Tube Carcinoma